Q2 2022 13F Holders as of 30 Jun 2022
-
Type / Class
-
Equity / Common Stock, par value $0.00001
-
Shares outstanding
-
62,162,717
-
Number of holders
-
125
-
Total 13F shares, excl. options
-
53,360,764
-
Shares change
-
+2,717,020
-
Total reported value, excl. options
-
$422,090,018
-
Value change
-
-$73,694,821
-
Put/Call ratio
-
19%
-
Number of buys
-
67
-
Number of sells
-
-70
-
Price
-
$7.91
Significant Holders of Protagonist Therapeutics, Inc - Common Stock, par value $0.00001 (PTGX) as of Q2 2022
177 filings reported holding PTGX - Protagonist Therapeutics, Inc - Common Stock, par value $0.00001 as of Q2 2022.
Protagonist Therapeutics, Inc - Common Stock, par value $0.00001 (PTGX) has 125 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 53,360,764 shares
of 62,162,717 outstanding shares and own 86% of the company stock.
Largest 10 shareholders include STATE STREET CORP (6,776,269 shares), RTW INVESTMENTS, LP (4,794,499 shares), Point72 Asset Management, L.P. (4,056,200 shares), FARALLON CAPITAL MANAGEMENT LLC (3,700,608 shares), FMR LLC (3,490,998 shares), BlackRock Inc. (3,454,916 shares), VANGUARD GROUP INC (2,734,765 shares), JOHNSON & JOHNSON (2,449,183 shares), Bain Capital Life Sciences Investors, LLC (2,260,572 shares), and MORGAN STANLEY (1,776,438 shares).
This table shows the top 125 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.